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Interactions between two a-toxins and the synthetic peptides al79-191 from both calf and human acetylcholine receptor 
a-subunit sequences have been studied by measurements of quenching of intrinsic fluorescence after toxin addition. Disso- 
ciation constants of approx. 5 x lo-* M for binding of calf peptide by both a-cobratoxin and erabutoxin a have been 
estimated. The binding of a-cobratoxin to calf peptide, which leads to marked quenching of fluorescence intensity, is 
inhibited by a 104 molar excess of acetylcholine. The human al79191 peptide binds to a-cobratoxin, but not, under 
comparable conditions, to erabutoxin a. 
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1. INTRODUCTION 
The nicotinic AChR, a multi-subunit membrane 
protein, (Y&-J& is a pentameric array of ‘four highly 
homologous subunits. The a-subunit contains the 
competitive binding site for both normal 
neurotransmitter, ACh, and for the protein snake 
venom a-toxins, which block neuromuscular 
transmission [l]. In a series of studies, the struc- 
ture of the reactive site of one toxin has been 
employed as prototype stereochemical probe of 
receptor [2-41. These studies have led directly to 
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identification of one AChR a-subunit sequence as 
the probable complementary site of toxin binding 
]4]. The initial requirement imposed by the toxin 
reactive site stereochemistry was that the ex- 
tracellular a-subunit toxin-binding domain should 
include a unique or uniquely located Trp residue 
absent from the corresponding ,&, y- or J-subunit 
sequences. Two such residues, Trp-184 and 
Trp-187, occur in the unique sequence (Y 
Val-177-Cys-193 of Torpedo californica [5-71, an 
a-segment, highly conserved in five other species, 
which satisfies all conformational and interactive 
requirements imposed by the toxin stereochemistry 
[4]. In the anomalous human cu-subunit sequence, 
residue 187 is Ser. 
This communication describes evidence which 
confirms our designation of one continuous pep- 
tide chain segment, CY Val-177-Cys-193, as prime 
toxin-binding domain. Two mammalian sequence 
peptides have been synthesized and their binding 
interactions with both long chain cu-CbTX and 
short chain Ea, studied using intrinsic fluorescence 
techniques. These techniques have been used to 
study AChR binding of both ACh and toxins [8,9]. 
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2. MATERIALS AND METHODS 
a-CbTX (Nuju naju &men&) was obtained from the Miami 
Serpentarium, Salt Lake City, UT; Ea (Laticauda sem$miata) 
was a gift from Professor Nobuo Tamiya. The purity of both 
toxins was confirmed by reverse-phase HPLC. Peptides were 
synthesized with both calf and human AChR cu-subunit 
179-191 sequences [lo]. The human sequence synthesized dif- 
fers from the calf sequence shown below only at LY Ser-187 and 
cy Thr-189. 
Calf: Lys(l79)-Glu-Ser-Arg-Gly-Trp(l84)-Lys-His-Trp(l87)- 
Val-Phe-Tyr-Ala( 191) 
To enhance peptide solubility and to avoid possible disruptive 
conformational effects, neither the N-terminal Val-177 lle-178 
nor the C-terminal Cys-192 Cys-193 dipeptide regions of the 
target segment 177-193 were included in the syntheses. To 
avoid problems in synthesis of human peptide, Ser-191 was 
replaced by Ala as in calf. The calf (Y 179-191 AChR peptide 
was synthesized with an Applied Biosystems 43QA automated 
synthesizer, and purified by ion exchange (Pharmacia FPLC 
mono-Q column) followed by reverse-phase HPLC. The human 
LY 179-191 AChR peptide was synthesized by an updated pro- 
cedure Ill], and purified by gel filtration followed by two 
reverse-phase HPLC separations. Amino acid and sequence 
analyses were used to establish purity and identity of both 
peptides. 
Fluorescence mission spectra were obtained at 23°C with the 
Perkin Elmer MFP66 spectrofluorometer using a 1 cm cell. 
Spectra were recorded over the range 320-495 run and averaged 
over 3-10 scans. The excitation wavelength associated with 
tryptophan fluorescence, 280 nm, was used except where noted. 
For studies with calf peptide, 2 x 5 nm or 3 x 5 nm slits were 
used to minimize photochemical decay; with the more weakly 
fluorescing human peptide, 5 x 5 nm slits were used. 
In each experiment, fluorescence spectra were obtained for a 
sample containing a fixed concentration (10-s-10-’ M) of calf 
or human peptide and sequentially increased toxin concentra- 
tions. Stock solutions (-10e5 M) of peptides and toxins were 
prepared in deionized and millipore filtered water (concentra- 
tions were established by amino acid analysis). In a typical ex- 
periment, after a baseline was established for 3.00 ml PBS at 
pH 7.4 in the sample cell, 5 ~1 of peptide stock solution were 
added and the peptide spectrum recorded; samples of toxin 
stock solution were then added sequentially, and the spectra 
recorded 20-40 min after each addition. Corresponding spectra 
for toxin alone were obtained either in separate xperiments, or 
by interpolation between standards. Total toxin to total peptide 
molar ratios varied from 0.1 to 6. 
The spectra of the mixtures were interpreted by the use of 
quenching curves, where the quenching, Q, at a given 
wavelength is given by the expression: Q = F,, + Ft - F,,,. Here 
Fp and Ft represent fluorescence intensity for peptide and toxin 
solutions, respectively, and F,,, the fluorescence intensity of the 
solutions when mixed. For simple 1: 1 peptide/toxin binding, 
the fraction of peptide bound, Ir, is given by x = Q/Qr, where 
QI_ is the limiting value of Q at high toxin concentrations 1121. 
If Qt. is estimated, the fraction x for each mixture can be 
evaluated. The dissociation constant, Kd, can then be calculated 
from the equation Kd = [P] *(b - x)’ (1 - x)/x, where b = 
[T]/lP], and [P] and [T] are the overall peptide and toxin con- 
centrations respectively. For interpretation of data from 
peptide*-CbTx solutions, where there were 6-10 separate 
observations, values for Kd and for a scale factor f = QrJl_P] 
were obtained by non-linear least squares tit of observed and 
calculated quenchings at the chosen wavelength (locally written 
program). 
In solutions containing a large excess of toxin, almost all pep- 
tide is bound, and fluorescence is mainly that from 
peptide-toxin complex plus unbound toxin. Thus, if toxin 
fluorescence remains relatively unchanged on binding, the dif- 
ference spectrum between that of the mixture and that of toxin 
alone may be considered the fluorescence spectrum of bound 
peptide. Changes in peptide Trp fluorescence on binding may 
thus be monitored as in studies with whole receptor [9]. For 
solutions containing a large excess of ACh, quenching was 
defined as before by Q = Ft + Fp - Fm where Ft, Fp and & now 
refer to fluorescence intensities in the presence of ACh. 
3. RESULTS 
3.1. Carf peptide cu-CbTX studies 
Spectra obtained after sequential addition of CY- 
CbTX to calf peptide solution show an initial 
decrease in peak fluorescence intensity, followed 
by an increase (fig.lA). Associated quenching 
curves all have the same shape and differ only in 
scale as expected for 1: 1 binding of toxin to pep- 
tide (see fig.2). Near saturation after final toxin 
addition is evident in fig.lB. Least squares 
analyses of the quenching data at 353 nm and at 
343 nm gave estimated Kd values of 6 x 10m8 M 
and 11 x lo-’ M, respectively. Analyses of data at 
353 and 340 nm from an independent experiment 
have Kd values of 2 x lo-* M at each wavelength. 
The average dissociation constant for these runs 
was approx. 5 x lo-’ M. 
In one experiment calf peptide was preincubated 
for 45 min with a 104 molar excess of ACh before 
toxin addition. This led to a sharp reduction in the 
toxin quenching effect (cf. la and lb in fig.2). 
Fluorescence of peptide solution alone was re- 
duced 20% in the presence of ACh. When ACh 
binds to the whole receptor there is a comparable 
7-8% reduction in fluorescence intensity 181. The 
observed inhibition of peptide binding by excess 
ACh and the ACh quenching of peptide 
fluorescence are both evidence of ACh binding by 
calf peptide. 
3.2. Calf peptide-Ea studies 
Data from two experiments with calf peptide 
and Ea, at 278 and 280 nm excitation wavelengths, 
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Fig.1. (A) Fluorescence spectra: (---) calf peptide (1.9 x 
lo-’ M), alone. Calf peptide after &ZbTX addition at selected 
concentrations of (1) 0.4, (2) 1 .l, (3) 3.0, (4) 5.8 and (5) 8.7 x 
10m7 M. Note blue shift in peak positions as toxin concentration 
is increased. (B) Saturation: quenching at 353 nm as function of 
toxin concentration. Smooth curves calculated using Kd = 5 X 
1O-8 M. 
established binding, with a dissociation constant 
between 2 and 5 x lo-* M. This range of values is 
similar to that estimated for calf peptide-cu-CbTX 
binding. As fig.3 shows, calf peptide fluorescence 
is more strongly quenched over the whole spectral 
range when long chain cu-CbTX binds than when 
short chain Ea binds. 
3.3. Human peptide-toxin studies 
It was more difficult to obtain quantitative data 
from studies with this peptide, since the intrinsic 
fluorescence of human peptide, measured under 
comparable conditions, is lower than that of calf 
peptide (fig.3). There is only one weakly fluoresc- 
ing Trp residue a 184 in human peptide. A ten- 
tative analysis of the results of preliminary 
investigations of human peptide-cu-CbTX interac- 
tions (278 nm excitation wavelength) suggested a 
Kd of approx. lo-’ M, which is somewhat larger 
than that for calf peptidee-CbTX interactions. 
Under comparable conditions no evidence of Ea 
binding by human peptide was found. Exhaustive 
studies were not made. 
325 350 3j5 400 425 
Emission Wavelength, nm 
Fig.2. Fluorescent quenching: ACh inhibition. Quenching 
curves for calf peptide (9.0 x 10-s M) with cu-CbTX 
(4.8 x10m7 M) in the absence (la) and in the presence (lb) of 
1.5 X 10-j M ACh, and, in the absence of ACh, with u-CbTX 
(1.7 x 10-r and 0.3 x 10e8 M), curves 2 and 3 respectively. 
Curves comparable to 2 and 3 (not shown) obtained in the 
presence of ACh lie very close to the baseline. 
L 
, 
325 
I I 1 
350 375 4Q0 
Emission Wavelength, nm 
Fig.3. Peptide fluorescence before and after binding. (1) Calf 
peptide fluorescence (0.9 x IO-’ M); (2) calf peptide 
fluorescence in association with Ea; (3) calf peptide 
fluorescence in association with cY-CbTX (2 and 3 prepared as 
described in text); (4) human peptide fluorescence (0.9 x 
1O-7 M). 
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4. DISCUSSION 
These experiments clearly establish that the 
AChR calf a-subunit synthetic peptide, cy 
179- 191, binds both long chain a-CbTX and short 
chain Ea, with dissociation constants of -5 x 
10m8 M in each case. Thus a short isolated segment 
of the a-subunit, first identified in terms of 
stereochemical requirements imposed by the toxin, 
binds these toxins as tightly as AChR binds both 
ACh and the curare alkaloids [13,14]. Further, 
with one toxin, a-CbTX, competitive binding by 
ACh has been demonstrated. The studies strongly 
support identification of the cy 179-191 segment as 
prime competitive AChR toxin-binding region [4]. 
The dynamic mode of toxin-receptor binding 
proposed earlier [4], which required that a receptor 
cy Trp residue enter and be bound in the ‘Trp’ cleft 
of the toxin reactive site, favored cy Trp-187 rather 
than (Y Trp-184 as cleft occupant. The experiments 
reported here suggest hat LY Trp-187 has indeed a 
major role in peptide/toxin binding interactions. 
The fluorescence intensity of calf peptide, with two 
LY Trp fluorophores, LY Trp-184 and Trp-187, is, on 
a molar basis, approx. 8-times greater than of 
human peptide, which lacks Q Trp-187. The 
enhanced calf peptide fluorescence may reasonably 
be associated with the Trp-187 contribution as 
dominant fluorophore. The sharp reduction of calf 
peptide fluorescence on binding, almost 50% for 
a-CbTX interactions, therefore reflects, in large 
part, a marked change in Q Trp-187 environment. 
Although the human LY 179-191 peptide lacks 
Trp-187 and does not bind the short chain Ea, it 
does bind, almost as tightly as calf peptide, to long 
chain CbTX. These findings follow the unusual 
pattern which characterises binding by intact 
human receptor. Thus, clinical observations [15] 
and biochemical experiments [16] have both im- 
plied or shown that long chain toxins do, and short 
chain toxins do not, bind to human receptor. The 
dilemma imposed by the assumption of one com- 
mon a-toxin binding mode [3] remains unsolved. It 
is possible that the long chain toxins can adopt a 
conformation adjusted to an atypical adaptive 
mode of binding to human AChR [4]. 
Designation of the cy 179-191 segment as prime 
competitive toxin-binding site is generally consis- 
tent with results of other studies. The whole ex- 
tracellular region of the w-subunit has been 
explored sequentially [ 17-201. The principal toxin- 
binding regions so identified overlap, at least par- 
tially, the segment LY 179-191. In one study a & of 
4 x lo-’ M was reported for a-CbTX binding to 
T. marmorata synthetic peptide, LY 185-196 [20]. 
The binding reported here for segment cy 179-191, 
which is three orders of magnitude tighter, em- 
phasizes the importance in multipoint toxin 
binding interactions of other residues besides a 
Trp-187 along the whole 179-191 segment. Work 
in progress seeks to establish structural details of 
these interactions. 
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